Active Biotech names new CEO

Sweden's Active Biotech announced that CEO Sven Andreasson has notified the board of his wish to resign. Tomas Leanderson, the company's CSO, has been named as the new president and CEO.

Shire announced that Dr. Jeffrey Jonas has been appointed senior vice president of R&D for its Specialty Pharmaceutical Business.

Bristol-Myers Squibb has appointed Quentin Roach as its new senior vice president and chief procurement officer.

MAP Pharmaceuticals has named Donald J. Kellerman, Pharm.D., to the position of senior vice president, clinical development and medical affairs.

VioQuest Pharmaceuticals has named Christopher Schnittker vice president and CFO.

Infinity Pharmaceuticals announced two leadership promotions within its executive leadership team: Michael S. Curtis, Ph.D. to vice president, pharmaceutical development and Jeanette Kohlbrenner to senior director, human resources. The company also named two new members to its board of directors: Martin Babler and Ian F. Smith.

Mylan has named Daniel E. Crookshank as vice president of nvestor relations.

Syntarga has named Dr. Nitin K. Damle as an advisor.

Akesis Pharmaceuticals has appointed Christos Mantzoros to its scientific advisory board.

Oncolin Therapeutics announced that Dr. Waldemar Priebe has agreed to join the Scientific Advisory Board as a member and to assume the role of a Chairman of the SAB.

Dr. Jeanne Loring has joined Histogen's scientific advisory board

Aldagen has named William E. Evans, PharmD to its board of directors.

Chemokine Therapeutics announced that Edward Taylor and Walter Korz have joined the board of directors.

Andrew J. Ferrara, chairman and chief executive officer of Boston Healthcare Associates, has been appointed to Sucampo Pharmaceuticals' board of directors.

GVK Biosciences said it has appointed Tarun Khanna to its board of directors. 

Velcura Therapeutics, Inc. CEO Michael Long, Ph.D., announced that William F. Brinkerhoff has joined the Board of Directors.

Innocoll Inc. today announced that Anthony H. Wild, Ph.D. has been appointed to its board of directors.

PDL BioPharma has named Gary A. Lyons to the company's board of directors.

Biophage Pharma has named Luc Dubois and Jocelyn R. Pelchat to its board of directors.

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.